Pathare, Anil <br/><br/>
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.  [electronic resource] 

 -  Annals of hematology  Apr 2010 
 - 405-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0584 
<br/><br/><label>Standard No.: </label>10.1007/s00277-009-0838-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Benzoates--therapeutic use<br/>Child<br/>Deferasirox<br/>Female<br/>Ferritins--blood<br/>Heart Diseases--complications<br/>Humans<br/>Iron--metabolism<br/>Iron Chelating Agents--therapeutic use<br/>Iron Overload--complications<br/>Liver--metabolism<br/>Magnetic Resonance Imaging<br/>Male<br/>Triazoles--therapeutic use<br/>Young Adult<br/>beta-Thalassemia--complications